What tests should a urothelial carcinoma patient get as part of their work up?
Daniel Petrylak, MD of Yale School of Medicine discusses which tests patients with urothelial carcinoma should receive as part of their cancer care at the 2017 ASCO Annual Meeting in Chicago, IL.
Author: obr
Added: 06/22/2017 (Source: Oncology Tube)
Source: Oncology Tube - June 22, 2017 Category: Cancer & Oncology Source Type: podcasts
If a urothelial carcinoma patient is progressing on checkpoint inhibitors, whats next for the patient?
Daniel Petrylak, MD of Yale School of Medicine discusses what's next for patient with bladder cancer after checkpoint inhibition therapy at the 2017 ASCO Annual Meeting in Chicago, IL.
Author: obr
Added: 06/22/2017 (Source: Oncology Tube)
Source: Oncology Tube - June 22, 2017 Category: Cancer & Oncology Source Type: podcasts
Checkpoint inhibition therapy in urothelial carcinoma cancer
Daniel Petrylak, MD of Yale School of Medicine discusses the role of checkpoint inhibition therapy in urothelial carcinoma cancer at the 2017 ASCO Annual Meeting.
Author: obr
Added: 06/22/2017 (Source: Oncology Tube)
Source: Oncology Tube - June 22, 2017 Category: Cancer & Oncology Source Type: podcasts
Should prostate cancer guidelines be updated based on the LATITUDE study?
Daniel Petrylak, MD of Yale School of Medicine discusses whether or not prostate cancer guidelines should be updated based on the new results of the LATITUDE study. This was recorded at the 2017 ASCO ...
Author: obr
Added: 06/22/2017 (Source: Oncology Tube)
Source: Oncology Tube - June 22, 2017 Category: Cancer & Oncology Source Type: podcasts
Impact of immunotherapies in the treatment of gastric & amp; GE junction cancers
Howard Hochster, MD of Yale Cancer Center discusses the impact of immunotherapy for the treatment of gastric and GE junction cancers at the 2017 ASCO Annual Meeting in Chicago, IL.
Author: obr
Added: 06/20/2017 (Source: Oncology Tube)
Source: Oncology Tube - June 20, 2017 Category: Cancer & Oncology Source Type: podcasts
Should stage lll colon cancer patients be treated with 3 months or 6 months of FOLFOX therapy?
Howard Hochster, MD of Yale Cancer Center discusses whether or not stage III colon cancer patients should be treated with either 3 months or 6 months of FOLFOX therapy. This was recorded at the 2017 A...
Author: obr
Added: 06/20/2017 (Source: Oncology Tube)
Source: Oncology Tube - June 20, 2017 Category: Cancer & Oncology Source Type: podcasts
New peri-operative regimen FLOT vs. ECX for gastric cancer patients
Howard Hochster, MD of Yale Cancer Center discusses new peri-operative treatment regimens for resectable gastric and GE junction cancers at the 2017 ASCO Annual Meeting in Chicago, IL.
Author: obr
Added: 06/20/2017 (Source: Oncology Tube)
Source: Oncology Tube - June 20, 2017 Category: Cancer & Oncology Source Type: podcasts
Approaches to treating BRAF-mutated positive CRC patients
Howard Hochster, MD of Yale Cancer Center gives an overview of treatments for BRAF-mutated positive colorectal cancer patients at the 2017 ASCO Annual Meeting in Chicago, IL.
Author: obr
Added: 06/20/2017 (Source: Oncology Tube)
Source: Oncology Tube - June 20, 2017 Category: Cancer & Oncology Source Type: podcasts
Results of the LUX Head and Neck 2 study
Barbara Ann Burtness, MD of Yale Cancer Center gives an overview of the LUX Head and Neck 2 trial, which was presented at the 2017 ASCO Annual Meeting in Chicago, IL.
Author: obr
Added: 06/19/2017 (Source: Oncology Tube)
Source: Oncology Tube - June 19, 2017 Category: Cancer & Oncology Source Type: podcasts
The Impact of Molecular Subsets on Adjuvant and Advanced Disease Treatment
Howard S. Hochster, MD of Yale School of Medicine gives an overview of his presentation, The Impact of Molecular Subsets on Adjuvant and Advanced Disease Treatment, which was discussed at the 2017 Gre...
Author: GiDebates2017
Added: 06/01/2017 (Source: Oncology Tube)
Source: Oncology Tube - June 1, 2017 Category: Cancer & Oncology Source Type: podcasts
Importance of Early Molecular Testing in Colon Cancer
Howard S. Hochster, MD of Yale School of Medicine discusses the importance of recommending molecular testing early on to patients with colon cancer. He further explains the significance of HER2 testin...
Author: GiDebates2017
Added: 06/01/2017 (Source: Oncology Tube)
Source: Oncology Tube - June 1, 2017 Category: Cancer & Oncology Source Type: podcasts
Impact of Molecular Testing on Upcoming Clinical Trials
Howard S. Hochster, MD of Yale School of Medicine discusses the impact of molecular testing and screening on potential clinical trials at the 2017 Great Debates and Updates in GI Malignancies in New Y...
Author: GiDebates2017
Added: 06/01/2017 (Source: Oncology Tube)
Source: Oncology Tube - June 1, 2017 Category: Cancer & Oncology Source Type: podcasts
EndNote Essential Training #6: Additional Styles and Customizing Styles
This video demonstrates how to find additional or updated styles on endnote.com and add them to your EndNote program, and how to modify an existing style to suit your needs.View Tutorial Full Size (8 min 02 sec)Download tutorial (MP4 file, 60.10MB) (Source: Tutorials from the Yale Medical Library)
Source: Tutorials from the Yale Medical Library - May 4, 2017 Category: Databases & Libraries Authors: Cushing / Whitney Medical Library Tags: EndNote Source Type: podcasts
Drug promotion, prescription, and value
Pharma companies say that money spent on promotion is essential to educate doctors about the best drugs - but when a medical student asked Joseph Ross, associate professor of medicine and public health at Yale, if those companies are promoting the right drugs for that message to be true, the answer wasn't available.
Ross and Tyler Greenaway, his... (Source: The BMJ Podcast)
Source: The BMJ Podcast - May 4, 2017 Category: General Medicine Authors: BMJ talk medicine Source Type: podcasts
